The phrase "advanced compound" is correct and usable in written English.
It can be used to describe a complex mixture or combination of elements, often in scientific or technical contexts.
Example: "The researchers developed an advanced compound that significantly improved the efficiency of solar panels."
Alternatives: "sophisticated mixture" or "complex formulation".
In terms of development, the most advanced compound is TLR4 antagonist E5564, which is in Phase III sepsis trials.
In contrast to the conventional optimized symmetric triangular rib, the advanced compound rib could improve the performance of heat transfer while minimizes the pressure drop.
In addition, probes now contain higher numbers of elements (e.g., high-density 18 L6, Siemens ACUSON) facilitating more versatile beam forming and providing the basis for increasingly advanced compound imaging.
Thus, there is a need for an advanced compound which would provide a good image using lowered-cost equipment (ultrasound, MRI), with no ionizing radiation and with good retention in the bladder for follow-up growth evaluation.
Several series of FFA1 agonists including TAK-875, the most advanced compound terminated in phase III studies due to concerns about liver toxicity, have been hampered by relatively high molecular weight and lipophilicity.
The most advanced compound, 1- 4- 5-benzhydryl-1H-tetrazol-1-yl butyl -4- 3-phenylpropyl piperazine (2i), was able to inhibit monoamine neurotransmitter reuptake in an in vitro test (IC50 = 1- 4- 5-benzhydryl-1H-tetrazol-1-yl butyl -4- 3-phenylpropyl piperazine
A sequence of in vitro assays followed by in vivo testing in validated animal models to assess the activity against Mycobacterium tuberculosis, pharmacology and toxicity is generally used for advancing compounds against tuberculosis in a preclinical stage.
An often cited criticism in advancing compounds to in vivo studies based on in vitro bactericidal effect is the lack of its predictive value.
These results provide the basis for a novel strategy of antimalarial drug development by advancing compounds that have dual mechanisms of action.
The author cited a need to develop pre-clinical models that are more predictive of human OA progression, or accept the risks associated with advancing compounds in development that demonstrate moderate results in already established models of OA.
While continuing to advance compounds into the expensive/expansive phase 3 arena undoubtedly represents risk principally to the drug developer, this should not be confused with a lack of concern or scientific interest from regulators.
